ژن تراپی مبتنی بر microRNA برای هدف قرار دادن PD-L1 روی سلول های توموری TNBC: زمانی برای تعریف راهکار جدید؟

مجریان: بهزاد برادران

خلاصه روش اجرا: We will conduct the systematic study according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (1). For this purpose, we will perform a systematic search on Embase, Scopus, PubMed, and Web of Science with the following keywords: ("BT20" OR "BT-549" OR "Cal51" OR "HCC 38" OR "HCC 1143" OR "HCC 1187" OR "HCC 1395" OR "HCC 1599" OR "HCC 1739" OR "HCC 1806" OR "HCC 1937" OR "HCC 2157" OR "HCC 2185" OR "HCC 3153" OR "HS578T" OR "MDA-MB-157" OR "MDA-MB-231" OR "MDA-MB-435" OR "MDA-MB-436" OR "MDA-MB-468" OR "SUM52PE" OR "SUM102PT" OR "SUM149PT" OR "Sum159PT" OR "SUM185PE" OR "SUM229PE" OR "SUM1315M02" OR "triple" OR "triple negative breast cancer" OR "triple-negative" OR "triple negative" OR "triple-negative breast cancer" OR "TNBC" OR "HCC70" OR "DU4475" OR "Hs 578T" OR "MDA-MB-453" OR "HCC1599" OR "HCC1937" OR "HCC1143" OR "HCC38" OR "HCC1806" OR "HCC1187" OR "HCC1395" OR "CRL-2331" OR "CRL-2336" OR "CRL-2321" OR "HTB-132" OR "CRL-2314" OR "CRL-2315" OR "CRL-2335" OR "CRL-2322" OR "HTB-123" OR "HTB-122" OR "HTB-126" OR "HTB-26" OR "HTB-130" OR "HTB-24" OR "HTB-131" OR "HTB-19" OR "CRL-2324") and ("programmed death-ligand 1" OR "PD-L1" OR "PD L1" OR "PDL1" OR "B7-H1" OR "B7 H1" OR "B7H1" OR "CD274" OR "cluster of differentiation 274" OR "CD 274" OR "cluster of differentiation274" OR "B7 homolog 1" OR "PDCD1 ligand 1" OR "PDCD1LG1" OR "PDCD1L1" OR "HPD-L1") and ("microRNA-" OR "microRNA" OR "micro RNA-" OR "micro RNA" OR "miRNA-" OR "miRNA" OR "miR-" OR "miR" OR "miRNA-" OR "miRNA") The keywords for the cell lines were obtained from the study conducted by Chavez et al (2). We will export all the obtained reords to our reference manager (Endnote X9.1) to consider them for inclusion in our systematic review. Following the systematic search, the obtained records will be selected in two phases. In phase I, the relevant records will be reviewed based on their titles/abstracts. In phase II, the full-texts of the remaining studies, along with their supplementary data, will be reviewed to consider them to be included in the systematic review. The following data will be extracted from the included studies: the first author, the publication year, the studied microRNA, the effect of microRNA on tumoral PD-L1 expression in TNBC cells, the effect of studied microRNA on TNBC cell/the tumor microenvironment of TNBC, and studied TNBC cell lines.